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Viral haemorrhagic fevers (VHFs) are caused by 
infection with one of a number of zoonotic RNA 
viruses. Although the aetiology of the infections may 
differ, the clinical presentation can be remarkably 
similar.[1] Patients typically experience nonspecific 
symptoms (especially early during the acute phase of illness) 
including fever of abrupt onset, headache, myalgia, lumbar pain, 
nausea, vomiting and diarrhoea. Progression to multisystem 
involvement is typically fairly rapid. Laboratory features of VHF 
include leucopenia, thrombocytopenia and elevated transaminases, 
while coagulation profiles become progressively abnormal and overt 
haemorrhagic features (ecchymoses, epistaxis, gingival bleeding, 
melaena, haematuria, etc.) may supervene from about day 5 after 
the onset of symptoms, or even earlier. Contrary to the name 
given to these conditions, haemorrhage is not a constant feature, 
as evidenced by the minority of patients who presented with 
overt haemorrhage during the current Ebola virus disease (EVD) 
outbreak.[2] A petechial or maculopapular rash may also appear from 
day 3 to 10, the exact timing of which varies with the virus concerned 
but is also related to the patient’s response to the infection. There are 
few or no specific treatments available, as antivirals and preventive 
and therapeutic vaccines remain in the developmental phase. For 
this reason, given the extremely high mortality rates and the highly 
infectious nature of VHFs (infectious doses are as low as one viral 
particle for some), the haemorrhagic fever (HF)-causing viruses have 
to be handled and stored in the highest biosafety- and security-level 
laboratory conditions, and patient management must adhere to 
stringent isolation and barrier nursing protocols. The appropriate 
use of adequate personal protective equipment (PPE) is critical in all 
instances. However, there is controversy regarding the type of PPE 
that should be used, as highlighted by the lack of consensus among 
role players in West Africa during the EVD outbreak. For example, 
the use of respirators (specifically N95 respirators) v. surgical masks 
is disputed, since most VHFs are not considered to be airborne.[3,4] 
Nevertheless, because aerosolisation is frequent during disinfection 
procedures, it is recommended that respirators be worn and that 
healthcare workers be observed by infection control staff to reduce 
transmission that occurs from contact of the virus with the face or 
neck, most frequently during removal of PPE or on inadvertently 
touching the face.
In Africa, the HF viruses belong to one of three families, namely 
the Arenaviridae (Lassa and Lujo viruses), Bunyaviridae (Crimean-
Congo haemorrhagic fever (CCHF) and Rift Valley fever (RVF) 
viruses) and Filoviridae (Ebola and Marburg viruses). In general 
these diseases are limited to specific areas, and outbreaks most often 
occur in fairly isolated and rural settings. However, as demonstrated 
during the current EVD outbreak, increasing interconnectedness and 
ease of travel render the occurrence of VHFs a possibility anywhere 
in the world. Although the risk of importation into South Africa 
(SA) is considered to be low,[5] the fact that considerable travel 
occurs between the rest of Africa and Johannesburg in particular, 
and vice versa, cannot be ignored. The indirect effects of VHF 
outbreaks have been demonstrated clearly during the ongoing 
West African EVD outbreak. Countries around the globe have 
been preparing their ports, healthcare systems and laboratories to 
detect and manage such cases at great financial cost, while travel 
restrictions and economic activities in numerous African economies 
(not just those directly affected) have also suffered.[6] Interestingly, 
this effect is disproportionate to the actual number of cases of EVD, 
which remains small compared with other formidable public health 
problems such as malaria, tuberculosis and HIV-AIDS.
The differential diagnosis of VHF is broad and may include many 
treatable infectious diseases, most notably malaria, bacteraemia 
(including meningococcaemia) and African tick bite fever, as well as 
non-infectious conditions such as haematological malignancies and 
heatstroke. The diagnostic approach must consider each possibility 
carefully, as delay in diagnosis increases the potential for mortality 
and transmission. As such, it is wise to maintain a high index of 
suspicion, especially for patients presenting with a compatible 
clinical syndrome and who have histories that indicate a risk of 
having contracted an HF-causing virus (such as travel to endemic 
regions or contact with animals, raw bushmeat, sick patients, etc.). 
The HF-causing viruses have a propensity to spread in the hospital 
setting, and delay in recognition may have dire effects.[1] A small 
number of nosocomial outbreaks have occurred in SA: Marburg virus 
disease (MVD) in Johannesburg in 1975, CCHF near Cape Town 
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in 1984, EVD in Johannesburg in 1996, and the Lujo virus, a newly 
identified arenavirus, in Johannesburg in 2008[7-10] (these are dealt 
with in detail in the ‘Clinical Alert’ article in this issue of SAMJ[11]).
Here we provide a concise account of VHFs, endemic and non-
endemic, of perceived importance to SA.
The bunyaviruses
CCHF is one of the most widely distributed VHFs, and has been 
described from more than 30 countries worldwide.[12] These include 
central, south-western and south-eastern Europe, the Middle East, 
Africa including SA, and more recently Malaysia.[12,13] The virus 
is typically ubiquitous in cattle-farming areas and corresponds 
to the distribution of the Hyalomma tick, the primary source of 
transmission. However, transmission also occurs following contact 
with infected animal blood or tissues, the majority of such cases 
having involved people in the livestock industry, such as agricultural 
and slaughterhouse workers and veterinarians.
In SA a total of 199 laboratory-confirmed cases of CCHF have 
been reported from 1981 to 2014 (data source: National Institute 
for Communicable Diseases, SA). These have been concentrated 
in the semi-arid farming areas of the Free State and Northern 
Cape provinces, although some have been recorded from all nine 
provinces. Interestingly, human cases remain relatively rare in SA, 
despite remarkably high seroprevalence rates in cattle and other 
ruminants.[14,15] Cases of nosocomial and laboratory transmission[8,16,17] 
have been noted on four occasions (data source: National Institute for 
Communicable Diseases) (see ‘Clinical Alert’[11]). An outbreak was 
reported in 1996 in which a total of 17 laboratory-confirmed cases 
occurred involving slaughterhouse workers following contact with 
infected ostriches.[18]
CCHF has a case fatality rate of 5 - 30%, and the clinical 
features, which are similar to those described above, are divided 
into four phases: incubation, pre-haemorrhagic, haemorrhagic and 
convalescence.[19,20] The incubation period is usually 1 - 5 days 
following tick bite and slightly longer following exposure to blood 
products. The pre-haemorrhagic phase is manifested by sudden 
onset of fever, muscle aches, back pain, headache, sore eyes and 
photophobia. As with all the VHFs there may be early sore throat, 
nausea, vomiting, diarrhoea, lymphadenopathy and abdominal 
pain with hepatomegaly, often followed by confusion and lethargy. 
Thereafter the haemorrhagic phase begins on day 3 - 6 with a 
petechial rash, purpura, ecchymoses and gastrointestinal and urinary 
tract bleeding. We have found that the majority of these cases initially 
present with leucopenia, thrombocytopenia occurring later in the 
disease process. At that time there may be a prolonged prothrombin 
time and activated partial prothrombin time (aPTT), and fibrin 
degradation products and D-dimers may be present. Hepatitis occurs 
with elevated transaminases (alanine (ALT) and aspartate (AST) 
transaminases). The disease is characterised by a diffuse capillary 
leak with hypovolaemia and acute kidney injury, and a fatal outcome 
may often be predicted by a persistently low platelet count, elevation 
of the AST and ALT to >200 and >150 IU/L, respectively, and of 
the aPTT to >60 seconds, and a decrease in the fibrinogen level to 
<110  mg/dL.[19] Bleeding and profound thrombocytopenia was a 
common finding in the SA cases, whereas in Central Europe clinical 
disease is highly variable with many mild cases reported.
The diagnosis is made by virus-specific reverse transcription-
polymerase chain reaction (RT-PCR) and is usually positive at 
the onset of symptoms, although in circumstances that are highly 
suggestive of the disease it should be repeated a few days later and 
barrier nursing continued.[11,21] Seroconversion may be expected 
from day 5 onwards, although this may be delayed in severe CCHF 
and may be a useful marker of prognosis.[19] Anti-CCHF antibodies 
may be measured by indirect immunofluorescence assays or enzyme-
linked immunofluorescence assays for IgG and IgM.[19,21]
Therapy for CCHF is primarily supportive, and although the 
therapeutic benefit of ribavirin has not been adequately supported 
by studies to date, it is nevertheless recommended that it be used 
early in the disease at a loading dose of 30 mg/kg, then 15 mg/kg 
every 6 hours (4 × 1 g) for 4 days, and then 7.5 mg/kg every 8 hours 
(4 × 0.5 g) for 6 days.[22] The argument against the use of ribavirin is 
based on its potential renal and hepatic toxicity and the anecdotal 
nature of data supporting its use.[23] Prevention of infection is based 
on prevention of tick exposures and use of appropriate PPE prior to 
contact with blood and tissues of ruminants in endemic areas. No 
vaccines are available.
RVF is caused by the mosquito-borne phlebovirus, also belonging 
to the family Bunyaviridae. The virus is widely distributed in Africa, 
including SA, but has also been reported from Saudi Arabia (after its 
introduction in 2000) and Madagascar.[24,25] The RVF virus has caused 
intermittent outbreaks in domestic and wildlife ruminant species 
and humans in SA.[26-29] The most recent outbreak in this country 
over the 4-year period 2008 - 2011 concluded with 25 deaths among 
302 laboratory-confirmed cases from all nine provinces (although 
most were from the Free State and Northern Cape).[28] RVF virus 
infection is typically asymptomatic or mild, manifesting as a febrile, 
flu-like syndrome with headache, nausea, myalgia and arthralgia. In 
a small proportion of cases, complications including encephalitis and 
HF may occur.[29] The latter manifest during the first week of illness 
and are accompanied by severe hepatic impairment. The fatality rate 
of the haemorrhagic form may be up to 50%. As with other VHFs, 
raised liver transaminases and thrombocytopenia generally precede 
death.[29,30]
Clinical diagnosis should be supported by specific laboratory 
testing, which includes RT-PCR, detection of anti-RVF virus IgG and 
IgM antibodies and virus isolation. Currently there is no accepted 
therapy for RVF and management is supportive only. In vivo studies 
of the antiviral favipiravir in small laboratory animals have shown 
promise.[31] No vaccines are commercially available to offer protection 
against RVF virus infection in humans.
The filoviruses
The filoviruses, EVD and MVD viruses, are known to cause highly 
fatal HF in humans and non-human primates.[32] To date five distinct 
viral species have been ascribed to the Ebolavirus genus, namely 
Zaire, Sudan, Taï Forest, Reston and Bundibudyo Ebola viruses.[33] 
These viruses vary enormously in terms of our current understanding 
of their geographical spread and also in their virulence in humans. 
For example, Reston Ebola viruses are not known to cause overt 
illness in humans (despite causing fatal HF in Asian non-human 
primates),[34] while Zaire Ebola viruses cause one of the most lethal 
infections known to mankind. The current West African outbreak is 
caused by a Zaire Ebola virus very similar to those that have caused 
previous outbreaks in the Democratic Republic of the Congo and 
Gabon.[35]
The natural ecology of Ebola viruses remains largely obscure. 
Evidence hints at a specific arboreal species of bat as the reservoir for 
the Zaire species,[36-38] but the specific mechanism of transfer from 
bat to human or bat to other forest-dwelling animals is not known. 
However, various human outbreaks have however been traced to 
contact with bushmeat, including the slaughtering of chimpanzees 
and bats.[39,40] The recent West African outbreak has been traced to 
a 2-year-old child in Guinea who may have had contact with bats 
while at play.[35,41] Once the virus enters the human population, 
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transmission is through direct contact with infected body fluids such 
as blood, faeces and vomitus. Owing to this mode of transmission, the 
virus has a propensity to spread in the hospital setting and between 
close contacts. More than 20 outbreaks of EVD have been reported 
since 1976.[42] Before 2014, these occurred in isolated settings with 
the largest involving 425 laboratory-confirmed cases reported from 
Gulu, Uganda, in 2000 and 2001.[42] By the end of March 2015, 
one year after the World Health Organization (WHO) declared an 
outbreak situation, the diseases had accounted for a total of 14 646 
laboratory-confirmed cases (and 24  754 in total if suspected and 
probable cases are included) and more than 10 000 deaths.[43] During 
this period more than 800 healthcare workers have contracted 
the disease, with nearly 500 losing their lives.[44] The scale of this 
outbreak has been exacerbated by poor socioeconomic conditions in 
the affected countries and an inadequate medical infrastructure that 
caused delays in the initial recognition of the disease and failure to 
respond timeously.[2] Consequently intensive international support 
on all fronts was, and continues to be, required.
Marburg virus is thought to be more widely distributed than Ebola 
virus, but despite this there have been only 12 outbreaks between 1967 
and 2014,[45] four of which consisted of single cases without further 
spread. There have been a total of 466 laboratory-confirmed cases 
with 373 deaths (an average fatality rate of 80%, range 23 - 100%). [45] 
The largest outbreak centered in Uige Province in Angola, with 
252 laboratory-confirmed cases from 2004 to 2005 with a 90% case 
fatality rate.[46] In six of the outbreaks, the epidemiological history 
implicated bats as the source of the infection and this was further 
reinforced by the finding of serological and molecular evidence of 
Marburg virus in the Egyptian fruit bat, Rousettus aegyptiacus.[47]
Clinically the signs and symptoms of EVD and MVD are not 
dissimilar to those of the other VHFs.[32,48-50] There are three phases: 
initially fever, headache, and myalgia, followed by diarrhoea, vomiting 
and dehydration; thereafter, in the second week, there may be 
recovery or deterioration with collapse, neurological manifestations 
and bleeding that can lead to a fatal outcome.
Fatal nosocomial infection with EVD and MVD has been 
reported in SA.[7,9] It is noteworthy that appropriate management 
limited the outbreaks to single secondary cases (see ‘Clinical 
Alert’[11]). Management of both diseases is supportive, involving 
active resuscitation and haemodynamic support. The usefulness 
of hyperimmune serum is uncertain, but it has been approved by 
the WHO for EVD in the context of the West African outbreak 
and clinical trials of various antiviral therapies are underway at the 
time of writing.[51] To date there are no licensed vaccines for the 
prevention of either EVD or MVD.[32,52,53] However, the extent of the 
current outbreak has led to the WHO expediting the evaluation and 
clinical validation of developmental vaccines. Since February 2015, 
case numbers have decreased leading to concerns that there may 
be insufficient healthcare workers and other volunteers to support 
clinical trial efforts in the affected countries.[54]
The arenaviruses
Before 2008, Lassa virus was the only arenavirus known to cause 
HF in Africa. The affected countries include Sierra Leone, Guinea, 
Liberia and Nigeria, where up to 500 000 cases are estimated to occur 
annually.[55,56] In West Africa, seroprevalence in select populations 
ranges from 8 - 52% in Sierra Leone and 4 - 55% in Guinea to 21% 
in Nigeria. Like other arenaviruses, Lassa virus is rodent-borne 
with the multimammate rat (Mastomys natalensis) the primary 
reservoir and vector of the disease. Transmission to the human 
population is mainly through aerolised urine and faecal matter that 
is contaminated with the virus.
Lassa fever has a variable clinical presentation from asymptomatic 
or mild infection to severe fatal HF in 20% of cases. Other common 
features include rigors, muscle pain, sore throat with exudates, 
nausea, vomiting, and chest and abdominal pain.[56-57] Haemorrhagic 
features may include bleeding from the gums and internal bleeding, 
although the latter has been reported in less than one-third of 
severe Lassa fever cases.[56] As with other VHFs, in severe cases 
progression is rapid to include multisystem dysfunction following 
an incubation period of 3 - 21 days.[56] A feature of fatal illness is 
impaired or delayed cellular immunity leading to fulminant viraemia 
and shock, associated with platelet and endothelial dysfunction.[56] 
The virus is excreted in urine for 3 - 9 weeks following infection and 
in semen for 3 months. Sensorineural hearing deficit may be found 
in 29% of cases v. zero in febrile controls.[57] Lymphocytopenia and 
a moderate thrombocytopenia occur and are maximal 10 - 11 days 
after symptom onset. Diagnosis is as for other VHFs, confirmed by 
specific laboratory testing involving RT-PCR, serology and virus 
isolation. Previously convalescent serum was used in the treatment of 
patients, but currently, if available, intravenous ribavirin may reduce 
mortality by up to 90%.[58] No vaccines exist for the prevention of 
infection with Lassa fever virus.
In 2008, a highly fatal outbreak of HF in Johannesburg was 
attributed to a previously unknown arenavirus, dubbed the Lujo virus 
(i.e. Lusaka-Johannesburg virus) (see ‘Clinical Alert’[11]).[10,59,60] The 
Lujo virus appears to have a particularly aggressive course[59] in that 
among the five reported cases there has been only one survivor. The 
incubation period is 9 - 13 days and is followed by fever, headache and 
myalgia, and thereafter by diarrhoea, pharyngitis and a morbiliform 
rash on the face and trunk, reported in three cases. Facial oedema 
also occurred in three patients, with marked pharyngeal ulceration in 
one. There appeared to be initial clinical improvement after hospital 
admission in three patients, followed by sudden, rapid deterioration 
in those who died. Bleeding was not a prominent feature in these 
cases. The sole survivor of the outbreak received treatment including 
intravenous ribavirin.[60] All the patients had thrombocytopenia on 
admission (range 42 - 104 × 109/L), and the transaminases were 
raised in all five at some point during the course of their illness.[60]
The diagnosis of Lassa or Lujo virus infections, as for other VHFs, 
is based on specific laboratory testing involving RT-PCR, serology 
and virus isolation.
Conclusion
It is predicted that VHFs will continue to emerge and re-emerge in the 
future. With the ease of global travel and increasing interconnectivity, 
the isolated African VHF outbreaks of the past have changed 
dramatically, and the risk of exporting these diseases to new locations 
is now well appreciated.
Although the risk of introduction of VHF cases is relatively low, 
Johannesburg remains the gateway to and from Africa. Vigilance and 
awareness of VHF are therefore necessary to ensure rapid clinical 
recognition and implementation of systems that allow for the rapid 
and accurate laboratory investigation and containment of potential 
outbreaks.
References
1. Ftika L, Maltezou HC. Viral haemorrhagic fevers in healthcare settings. J Hosp Infect 2013;83(3):185-
192. [http://dx.doi.org/10.1016/j.jhin.2012.10.013]
2. World Health Organization Ebola Response Team. Ebola virus disease in West Africa – the first 9 
months of the epidemic and forward projections. N Engl J Med 2014;371(16):1481-1495. [http://
dx.doi.org/ 10.1056/NEJMoa1411100]
3. MacIntyre CR, Chughtai AA, Seale H, Richards GA, Davidson PM. Uncertainty, risk analysis and 
change for Ebola personal protective equipment guidelines. Int J Nurs Stud 2014;2(5):899-903. [http://
dx.doi.org/10.1016/j.ijnurstu.2014.12.001]
4. MacIntyre CR, Chughtai AA, Seale H, Richards GA, Davidson PM. Respiratory protection for 
healthcare workers treating Ebola virus disease (EVD): Are facemasks sufficient to meet occupational 
750       September 2015, Vol. 105, No. 9
REVIEW
health and safety obligations? Int J Nurs Stud 2014;51(11):1421-1426. [http://dx.doi.org/10.1016/j.
ijnurstu.2014.09.002]
5. Weyer J, Blumberg LH. Ebola virus disease in West Africa – South African perspectives. S Afr Med J 
2014;104(11):754-755. [http://dx.doi.org/10.7196/SAMJ.9045]
6. Schar D, Daszak P. Ebola economics: The case for an upstream approach to disease emergence. 
EcoHealth 2015;11(4):451-452. [http://dx.doi.org/10.1007/s10393-015-1015-6]
7. Gear JS, Cassel GA, Gear AJ, et al. Outbreak of Marburg virus disease in Johannesburg. BMJ 
1975;4(5995):489-493.
8. Van Eeden PJ, Joubert JR, van de Wal BW. A nosocomial outbreak of Crimean-Congo haemorrhagic 
fever at Tygerberg Hospital: Part I. Clinical features. S Afr Med J 1985;68(10):711-717.
9. Richards GA, Murphy S, Jobson R, et al. Unexpected Ebola virus in a tertiary setting: Clinical and 
epidemiologic aspects. Crit Care Med 2000;28(1):240-244. [http://dx.doi.org/10.1097/00003246-
200001000-00041]
10. Paweska JT, Sewlall NH, Ksiazek TG, et al. Nosocomial outbreak of novel arenavirus infection, 
southern Africa. Emerg Infect Dis 2009;15(10):1598-1602. [http://dx.doi.org/10.3201/eid1510.090211]
11. Richards GA. Nososcomial transmission of viral haemorrhagic fever in South Africa. S Afr Med J 
2015;105(9):709-712. [http://dx.doi.org/10.7196/SAMJnew.8168]
12. Burt FJ, Goedhals D. Crimean-Congo haemorrhagic fever virus, an emerging and re-emerging 
pathogen. In: Sing A, ed. Zoonoses – Infections Affecting Humans and Animals. Dordrecht: Springer, 
2015:977-996. [http://dx.doi.org/10.1007/978-94-017-9457-2_39]
13. Lani R, Rahim NFM, Hassan H, et al. First report on the seroprevalence of the Crimean-Congo 
haemorrhagic fever virus, a tick-borne virus, in Malaysia’s Orang Asli population. Eur Rev Med 
Pharmacol Sc 2015;19(3):461-466.
14. Burt FJ, Swanepoel R, Braack LEO. Enzyme-linked immunosorbent assays for the detection of 
antibody to Crimean-Congo haemorraghic fever virus in sera of livestock and wild vertebrates. 
Epidemiol Infect 1993;111(3):547-557. [http://dx.doi.org/10.1017/s0950268800057277]
15. Swanepoel R, Shephard AJ, Leman PA, Shephard SP, Miller GB. A common-source outbreak of 
Crimean-Congo haemorrhagic fever on a dairy farm. S Afr Med J 1985;68(9):635-637.
16. Shepherd AJ, Swanepoel R, Shepherd SP, Leman PA, Blackburn NK, Hallett AF. A nosocomial outbreak 
of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. S Afr Med J 1985;68(10):733-736.
17. National Institute for Virology. Annual Report 1985. Johannesburg: Department of National Health 
and Population Development, 1986:24.
18. National Institute for Virology. Annual Report 1996. Johannesburg: Department of Health, 1997:14.
19. Swanepoel R, Gill DE, Shephard AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of 
Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989;11(Suppl 4):S794-S800. [http://dx.doi.
org/10.1093/clinids/11.supplement_4.s794]
20. Ergönül Ő. Crimean-Congo haemorrhagic fever. Lancet 2006;6(4):203-214. [http://dx.doi.org/10.1016/
s1473-3099(06)70435-2]
21. Tezer H, Polat M. Diagnosis of Crimean-Congo haemorrhagic fever. Exp Rev Anti Infect Ther 
2015;13(15):555-556. [http://dx.doi.org/10.1586/14787210.2015.1021782]
22. Ergönül Ő. Evidence supports ribavirin use in Crimean-Congo hemorrhagic fever. Int J Infect Dis 
2014;29:296. [http://dx.doi.org/10.1016/j.ijid.2014.08.016]
23. Ceylan B, Turhan V. The efficacy of ribavirin in Crimean-Congo hemorrhagic fever – randomized trials 
are urgently needed. Int J Infect Dis 2014;29:297-298. [http://dx.doi.org/10.1016/j.ijid.2014.08.015]
24. Clements ACA, Pfeiffer DU, Martin V, Otte MJ. A Rift Valley fever atlas for Africa. Prev Vet Med 
2007;82(1-2):72-82. [http://dx.doi.org/10.1016/j.prevetmed.2007.05.006] 
25. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): 
An update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 
2010;41(6):61. [http://dx.doi.org/10.1051/vetres/2010033]
26. Swanepoel R, Coetzer JAW. Rift Valley fever. In: Coetzer JAW, Tustin RC, eds. Infectious Diseases of 
Livestock. 2nd ed. Cape Town: Oxford University Press, 2005:1037-1070.
27. Archer VN, Weyer J, Paweska J, et al. Outbreak of Rift Valley fever affecting veterinarians and farmers 
in South Africa, 2008. S Afr Med J 2011;101(4):263-266.
28. Archer BN, Thomas J, Weyer J, et al. Epidemiologic investigations into outbreaks of Rift Valley 
fever in humans, South Africa, 2008-2011. Emerg Infect Dis 2013;19(12):1918-1924. [http://dx.doi.
org/10.3201/eid1912.121527]
29. Paweska JT. Rift Valley fever. In: Ergönül Ő, Can F, Akova M, Madoff L, eds. Emerging Infectious 
Diseases: Clinical Case Studies. London: Academic Press,2014:73-93.
30. Al Hazmi M, Ayooka EA, Abdurahman M, et al. Epidemic Rift Valley fever in Saudi Arabia: A 
clinical study of severe illness in humans. Clin Infect Dis 2003;36(3):245-252. [http://dx.doi.
org/10.1086/345671]
31. Scharton D, Bailey KW, Vest Z, et al. Favipiravir (T-705) protects against peracute Rift Valley fever 
virus infection and reduces delayed-onset neurological diseases observed with ribavirin treatment. 
Antiviral Res 2014;104(April):84-92. [http://dx.doi.org/ 10.1016/j.antiviral.2014.01.016]
32. Rougeron V, Feldmann H, Grard G, et al. Ebola and Marburg haemorrhagic fever. J Clin Virol 
2015;64:111-119. [http://dx.doi.org/10.1016/j.jcv.2015.01.014]
33. Barrette RW, Xu L, Rowland JM, McIntosh MT. Current perspectives on the phylogeny of Filoviridae. 
Infect Genet Evol 2011;11(7):1514-1519. [http://dx.doi.org/ 10.1016/j.meegid.2011.06.017]
34. Morikawa S, Saijo M, Kurane I. Current knowledge on lower virulence of Reston Ebola virus (a 
review). Comp Immunol Microbiol Infect Dis 2007;30(5-6):391-398. [http://dx.doi.org/10.1016/j.
cimid.2007.05.005]
35. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea – preliminary 
report. N Engl J Med 2014;371(15):1418-1428. [http://dx.doi.org/ 10.1056/NEJMoa1404505]
36. Pourrut X, Kumulungui B, Wittmann T, et al. The natural history of Ebola virus in Africa. Microbes 
Infect 2005;7(7-8):1005-1014. http://dx.doi.org/10.1016/j.micinf.2005.04.006]
37. Groseth A, Feldmann H, Strong JE. The ecology of Ebola viruses. Trends Microbiol 2007;15(9):408-
416. [http://dx.doi.org/10.1016/j.tim.2007.08.001]
38. Olival KJ, Hayman DT. Filoviruses in bats: Current knowledge and future directions. Viruses 
2014;6(4):1759-1788. [http://dx.doi.org/10.3390/v6041759]
39. World Health Organization. Outbreak(s) of Ebola haemorrhagic fever, Congo and Gabon, October 
2001-July 2002. Wkly Epidemiol Rec 2003;78(26):223-225.
40. World Health Organization. WHO declares end of Ebola outbreak in the Democratic Republic of 
Congo. http://www.who.int/mediacentre/news/statements/2014/drc-ends-ebola/en/ (accessed 17 
December 2014).
41. Saéz M, Weiss S, Nowak K, et al. Investigating the zoonotic origin of the West African Ebola epidemic. 
EMBO Mol Med 2014;7(1):17-23. [http://dx.doi.org/10.15252/emmm.201404792]
42. Centers for Disease Control and Prevention. Outbreaks chronology: Ebola virus disease. http://www.
cdc.gov/vhf/ebola/outbreaks/history/chronology.html (accessed 23 March 2015).
43. Centers for Disease Control and Prevention. 2014 Ebola outbreak in West Africa – case counts. http://
www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html (accessed 23 March 2015).
44. World Health Organization. Ebola situation report – 18 March 2015. http://apps.who.int/ebola/
current-situation/ebola-situation-report-18-march-2015 (accessed 23 March 2015).
45. Centers for Disease Control and Prevention. Chronology of Marburg hemorrhagic fever outbreaks. 
http://www.cdc.gov/vhf/marburg/resources/outbreak-table.html (accessed 23 March 2015).
46. Centers for Disease Control and Prevention. Outbreak of Marburg virus hemorrhagic fever – Angola. 1 
October 2004-29 March 2005. MMWR Morb Mortal Wkly Rep 2005;54(12):308-309.
47. Towner JS, Pourrut X, Albariño CG, et al. Marburg virus infection detected in a common African bat. 
PLoS One 2007;8:e764. [http://dx.doi.org/10.1371/journal.pone.0000764]
48. Hartman AL, Towner JS, Nichol ST. Ebola and Marburg hemorrhagic fever. Clin Lab Med 
2010;30(1):161-177. [http://dx.doi.org/10.1016/j.cll.2009.12.001]
49. Beeching NJ, Fenech M, Houlihan C. Ebola virus disease. BMJ 2014;349:g7348. [http://dx.doi.
org/10.1136/bmj.g7348]
50. Formenty P. Ebola virus disease. In: Ergönül O, Can F, Akova M, Madoff L, eds. Emerging Infectious 
Diseases, Clinical Case Studies. London: Academic Press, 2014:121-134.
51. Gulland A. First Ebola treatment is approved by WHO. BMJ 2014;349:g5539. [http://dx.doi.
org/10.1136/bmj.g5539]
52. Reed DS, Mohamadzadeh M. Status and challenges of filovirus vaccines. Vaccine 2007;25(11):1923-
1934. [http://dx.doi.org/10.1016/j.vaccine.2006.11.037]
53. Sridhar S. Ebola and Marburg vaccines for Africa: One step closer. Lancet 2014;385(9977):1491-1493. 
[http://dx.doi.org/10.1016/S0140-6736(14)62445-4]
54. MacKenzie D. Ebola’s retreat thwarts drug and vaccines trails. New Sci 2015;225(3008):14. [http://
dx.doi.org/10.1016/S0262-4079(15)60292-5]
55. Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in West African sub-region: An overview. J Vector 
Born Dis 2007;44(1):1-11.
56. Richmond JK, Baglole DJ. Clinical Review. Lassa fever: Epidemiology, clinical features, and social 
consequences. BMJ 2003;327:1271. [http://dx.doi.org/10.1136/bmj.327.7426.1271]
57. McCormick JB, King IJ, Webb PA, et al. A case-control study of the clinical diagnosis and course of 
Lassa fever. J Infect Dis 1987;155(3):445-455.
58. McCormick JB, King IJ, Webb PA, et al. Lassa fever: Effective therapy with ribavirin. N Engl J Med 
1986;314(1):20-26.
59. Paweska JT, Jansen van Vuren P, Weyer J. Lujo hemorhagic fever. In: Singh SK, Ruzek D, eds. Viral 
Haemorrhagic Fevers. 1st ed. Boca Raton, FL: CRC Press, 2013:287-305.
60. Sewlall NH, Richards GA, Duse A, et al. Clinical features and patient management of Lujo haemorrhagic 
fever. PLoS Negl Trop Dis 2014;8(11):e3233. [http://dx.doi.org/10.1371/journal.pntd.0003233]
Accepted 13 July 2015.
751       September 2015, Vol. 105, No. 9
